Typically, there are two strategies to stimulate T-cells activation: (1) expansion of T-cells isolated from lymphocytes of a cancer patient under ex vivo condition and then reinsertion of these T-cells into the patient (Broere and van Eden, 2019), and (2) to design nanovaccines for the tumor-specific CD8+ T cells activation (Zhang et al., 2017). Here, CD8A is linked to cancer.